Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | ITGAV | P06756 | 4/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 10/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.35 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6019179 | 0.92 | HDAC1 (0.55) | HDAC1HDAC6ITGAVITGB3CXCR4 | |
| SCHEMBL6018210 | 0.91 | CXCR4 (0.39) | HDAC1HDAC6ITGAVITGB3CXCR4 | |
| SCHEMBL7024499 | 0.90 | HDAC1 (0.42) | HDAC1HDAC6ITGAVITGB3CXCR4 | |
| SCHEMBL6018159 | 0.85 | HDAC1 (0.41) | HDAC1HDAC6ITGAVITGB3CXCR4 | |
| SCHEMBL6018125 | 0.84 | HDAC1 (0.40) | HDAC1HDAC6ITGAVCXCR4CYP3A4 | |
| SCHEMBL6018202 | 0.84 | CXCR4 (0.47) | HDAC1HDAC6ITGAVITGB3CXCR4 | |
| SCHEMBL6018478 | 0.82 | CXCR4 (0.36) | HDAC1HDAC6ITGAVCXCR4CYP3A4 | |
| SCHEMBL6018557 | 0.81 | HDAC1 (0.43) | HDAC1HDAC6ITGAVITGB3CXCR4 | |
| SCHEMBL6681763 | 0.81 | HDAC1 (0.45) | HDAC1HDAC6CXCR4CYP3A4CYP2D6 | |
| SCHEMBL6018137 | 0.80 | HDAC1 (0.53) | HDAC1HDAC6ITGAVITGB3CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098215-B2 | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20040092556-A1 | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CORPORATION (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1273571-A1 | NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME | Kureha Chemical Industry Co., Ltd. (JP) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092556-A1 | Nitrogenous compounds and antiviral drugs containing the same | NSUN2, ZC3HAV1L, PNP | HDAC1 651/4885HDAC6 3064/4885ITGAV 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.